DOW JONES26,957.59-123.77 -0.46%
S&P 5003,116.39-11.82 -0.38%
NASDAQ8,980.78+15.16 0.17%

Allergan Reports Q4 Earnings Beat

Allergan plc (NYSE: AGN) reported quarterly earnings of $5.22 per share on Monday, beating the analyst consensus estimate of $4.57 by 14.22%. This is a 21.68% increase over earnings of $4.29 per share in the same period last year.

Benzinga · 02/10/2020 14:00

Allergan plc (NYSE: AGN) reported quarterly earnings of $5.22 per share on Monday, beating the analyst consensus estimate of $4.57 by 14.22%.

This is a 21.68% increase over earnings of $4.29 per share in the same period last year.

The company reported quarterly sales of $4.351 billion, beating the analyst consensus estimate of $4.09 billion by 6.38%. This is a 6.64% increase over sales of $4.08 billion the same period last year.
"I am proud of Allergan's colleagues who achieved many important milestones in 2019 that will make a difference to patients for years to come," CEO Brent Saunders said in a statement.

"They achieved FDA approval of Ubrelvy, a first-in-class oral treatment for migraine; two new approvals for Botox for pediatric spasticity; approval for Vraylar for bipolar depression; and filings for two new eye care drugs

Bimatoprost SR for glaucoma and Abicipar for Age-related Macular Degeneration."

Allergan shares were trading up slightly at $197.23 at the time of publication in Monday's premarket session. The stock has a 52-week high of $197 and a 52-week low of $114.27.

Related Links:

Allergan Reports Q2 Earnings Beat, Reaffirms Guidance